The UK and US have secured a landmark trade agreement that will maintain no import taxes on UK medicine shipments entering the US market.
Agreement Details of the Deal
As part of the deal, the UK has committed to raise expenditure on medicines through the public health system. This move ensures that duties on these crucial exports will stay at zero for a timeframe of the next three years.
This agreement is in response to earlier warnings to dramatically increase import taxes on branded pharmaceutical imports, with increases floated reaching 100%.
"This agreement with the United Kingdom bolsters the global environment for new treatments and establishes long-overdue fairness to American-British medicine commerce," a statement said.
Trade Impact
Drugs are one of the UK's most significant export categories to the US, which is by far the largest market for leading companies like GSK and AstraZeneca.
Trade data indicate that in the one-year period prior to last September, the UK sold drugs totaling £11.1bn to the US. This value accounted for nearly one-fifth of British export trade in that span.
"This agreement safeguards jobs, stimulates capital expenditure and sets the stage for the UK to establish itself as a global hub for biotech and pharma," a government official stated.
Detailed NHS Changes
The deal entails several specific commitments from the British government:
- Revised Affordability Limit: The UK will lift the price threshold at which it considers new therapies to be unaffordable by twenty-five percent.
- Increased NHS Spending: There is a aim to raise total public funding on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Payback Limit: The amount manufacturers must return to the NHS to prevent overspending will be capped at 15%. In the past, rebates were more than 20%.
Broader Context
The pact takes place against a long-running tension between the pharmaceutical industry and the UK government over medicine costs and approval rates.
This friction were exacerbated by arguments that US patients were paying significantly more for the equivalent treatments than consumers in the Britain and the EU.
In recent months, several major pharmaceutical investments in the UK have been paused or abandoned, while major funding commitments have been announced toward projects in the United States.
The Science Minister stated that the NHS needed to increase expenditure on medicines, noting that its budget allocation on drugs had shrunk as a percentage of its overall budget over the previous ten-year period.
